Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth

Virology

Volumn 393, Issue 1, 2009, Pages 112-119

  Gustchina, Elena ^a   Louis, John M ^a   Frisch, Christian ^b   Ylera, Francisco ^b   Lechner, Annette ^b   Bewley, Carole A ^a   Clore, G Marius ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b MORPHOSYS AG   (Germany)

Author keywords

Affinity maturation; Broadly neutralizing antibodies; gp41 envelope; HIV 1; Naive phage library

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 41;

ANTIBODY AFFINITY; ANTIBODY LIBRARY; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; DIRECTED MOLECULAR EVOLUTION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349380779     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.07.019     Document Type: Article

References (57)

1. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
2. Bewley C.A., Louis J.M., Ghirlando R., and Clore G.M. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277 (2002) 14238-14245
3. Caffrey M., Cai M., Kaufman J., Stahl S.J., Wingfield P.T., Covell D.G., Gronenborn A.M., and Clore G.M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17 (1998) 4572-4584
4. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
5. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
6. Chan D.C., Chutkowski C.T., and Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15613-15617
7. Chen C.H., Greenberg M.L., Bolognesi D.P., and Matthews T.J. Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res. Hum. Retroviruses 16 (2000) 2037-2041
8. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan Jr. G.V., and Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 (2007) 79-90
9. Chou T.C., and Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115 (1981) 207-216
10. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22 (1984) 27-55
11. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
12. Eckert D.M., and Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11187-11192
13. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., and Kim P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 (1999) 103-115
14. Eckert D.M., Shi Y., Kim S., Welch B.D., Kang E., Poff E.S., and Kay M.S. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci. 17 (2008) 2091-2100
15. Freed E.O., Myers D.J., and Risser R. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J. Virol. 63 (1989) 4670-4675
16. Furuta R.A., Wild C.T., Weng Y., and Weiss C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nature Struct. Biol. 5 (1998) 276-279
17. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 (2003) 36-50
18. Golding H., Zaitseva M., de Rosny E., King L.R., Manischewitz J., Sidorov I., Gorny M.K., Zolla-Pazner S., Dimitrov D.S., and Weiss C.D. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76 (2002) 6780-6790
19. Gustchina E., Louis J.M., Bewley C.A., and Clore G.M. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. J. Mol. Biol. 364 (2006) 283-289
20. Gustchina E., Louis J.M., Lam S.N., Bewley C.A., and Clore G.M. A monoclonal Fab derived from a human non-immune phage library reveals a new epitope on gp41 and neutralizes diverse HIV-1 strains. J. Virol. 81 (2007) 12946-12953
21. Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J. Virol. 82 (2008) 10032-10041
22. Haenel C., Satzger M., Ducata D.D., Ostendorp R., and Brocks B. Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration. Anal. Biochem. 339 (2005) 182-184
23. Hamburger A.E., Kim S., Welch B.D., and Kay M.S. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280 (2005) 12567-12572
24. Jarutat T., Frisch C., Nickels C., Merz H., and Knappik A. Isolation and comparative characterization of Ki-67 equivalent antibodies from the HuCAL phage display library. Biol. Chem. 387 (2006) 995-1003
25. Jiang S., Lin K., Strick N., and Neurath A.R. HIV-1 inhibition by a peptide. Nature 365 (1993) 113
26. Jiang S., Lin K., and Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72 (1998) 10213-10217
27. Karlsson G.B., Gao F., Robinson J., Hahn B., and Sodroski J. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J. Virol. 70 (1996) 6136-6142
28. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., Hoess A., Wolle J., Pluckthun A., and Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296 (2000) 57-86
29. Kretzschmar T., and von Ruden T. Antibody discovery: phage display. Curr. Opin. Biotechnol. 13 (2002) 598-602
30. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005) 10108-10125
31. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., and Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80 (2006) 1414-1426
32. CCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 276 (2001) 29485-29489
33. Louis J.M., Nesheiwat I., Chang L., Clore G.M., and Bewley C.A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278 (2003) 20278-20285
34. Louis J.M., Bewley C.A., Gustchina E., Aniana A., and Clore G.M. Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J. Mol. Biol. 353 (2005) 945-951
35. Luftig M.A., Mattu M., Di Giovine P., Geleziunas R., Hrin R., Barbato G., Bianchi E., Miller M.D., Pessi A., and Carfi A. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Struct. Mol. Biol. 13 (2006) 740-747
36. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79 (2005) 10103-10107
37. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., and Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Rev. Drug Discov. 3 (2004) 215-225
38. Melikyan G.B., Egelhofer M., and von Laer D. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J. Virol. 80 (2006) 3249-3258
39. Miller M.D., Geleziunas R., Bianchi E., Lennard S., Hrin R., Zhang H., Lu M., An Z., Ingallinella P., Finotto M., Mattu M., Finnefrock A.C., Bramhill D., Cook J., Eckert D.M., Hampton R., Patel M., Jarantow S., Joyce J., Ciliberto G., Cortese R., Lu P., Strohl W., Schleif W., McElhaugh M., Lane S., Lloyd C., Lowe D., Osbourn J., Vaughan T., Emini E., Barbato G., Kim P.S., Hazuda D.J., Shiver J.W., and Pessi A. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14759-14764
40. Nelson J.D., Kinkead H., Brunel F.M., Leaman D., Jensen R., Louis J.M., Maruyama T., Bewley C.A., Bowdish K., Clore G.M., Dawson P.E., Frederickson S., Mage R.G., Richman D.D., Burton D.R., and Zwick M.B. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377 (2008) 170-183
41. O'Doherty U., Swiggard W.J., and Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74 (2000) 10074-10080
42. Pluckthun A. Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol. Rev. 130 (1992) 151-188
43. Rauchenberger R., Borges E., Thomassen-Wolf E., Rom E., Adar R., Yaniv Y., Malka M., Chumakov I., Kotzer S., Resnitzky D., Knappik A., Reiffert S., Prassler J., Jury K., Waldherr D., Bauer S., Kretzschmar T., Yayon A., and Rothe C. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J. Biol. Chem. 278 (2003) 38194-38205
44. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., and Doms R.W. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16249-16254
45. Root M.J., and Steger H.K. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 10 (2004) 1805-1825
46. Root M.J., Kay M.S., and Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 291 (2001) 884-888
47. Rothe C., Urlinger S., Lohning C., Prassler J., Stark Y., Jager U., Hubner B., Bardroff M., Pradel I., Boss M., Bittlingmaier R., Bataa T., Frisch C., Brocks B., Honegger A., and Urban M. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J. Mol. Biol. 376 (2008) 1182-1200
48. Steger H.K., and Root M.J. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281 (2006) 25813-25821
49. Steidl S., Ratsch O., Brocks B., Durr M., and Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol. Immunol. 46 (2008) 135-144
50. Sullivan N., Sun Y., Li J., Hofmann W., and Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69 (1995) 4413-4422
51. Tan K., Liu J., Wang J., Shen S., and Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12303-12308
52. Virnekas B., Ge L., Pluckthun A., Schneider K.C., Wellnhofer G., and Moroney S.E. Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res. 22 (1994) 5600-5607
53. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., and Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 (1997) 426-430
54. Wild C., Oas T., McDanal C., Bolognesi D., and Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10537-10541
55. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9770-9774
56. Williamson C., Morris L., Maughan M.F., Ping L.H., Dryga S.A., Thomas R., Reap E.A., Cilliers T., van Harmelen J., Pascual A., Ramjee G., Gray G., Johnston R., Karim S.A., and Swanstrom R. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19 (2003) 133-144
57. Zhang M.Y., Vu B.K., Choudhary A., Lu H., Humbert M., Ong H., Alam M., Ruprecht R.M., Quinnan G., Jiang S., Montefiori D.C., Mascola J.R., Broder C.C., Haynes B.F., and Dimitrov D.S. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J. Virol. 82 (2008) 6869-6879